Literature DB >> 16989922

Nodule management protocol of the NELSON randomised lung cancer screening trial.

Dong Ming Xu1, Hester Gietema, Harry de Koning, René Vernhout, Kristiaan Nackaerts, Mathias Prokop, Carla Weenink, Jan-Willem Lammers, Harry Groen, Matthijs Oudkerk, Rob van Klaveren.   

Abstract

In December 2003, the Dutch-Belgian NELSON trial, a Dutch acronym for "Nederlands-Leuvens Longkanker Screenings ONderzoek", has been launched. Primary objective of the NELSON trial is to investigate whether screening for lung cancer by 16-detector multi-slice CT with 16 mm x 0.75 mm collimation and 15 mm table feed per rotation (pitch=1.5) in year 1, 2 and 4 will lead to a decrease in lung cancer mortality in high risk subjects of at least 25% compared to a control group which receives no screening. In this paper, the screening regimen and the classification and management of the screen-detected nodules at baseline and incidence screening is presented. This is the first large lung cancer screening trial in which the nodule management protocol is based on volumetric nodule assessment and the presence or absence of growth. Furthermore, the quality assurance measures and the NELSON management system (NMS) are presented.

Entities:  

Mesh:

Year:  2006        PMID: 16989922     DOI: 10.1016/j.lungcan.2006.08.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  82 in total

1.  The impact of radiologists' expertise on screen results decisions in a CT lung cancer screening trial.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk; Pim A de Jong; Willem P Mali; Harry J M Groen; Rozemarijn Vliegenthart
Journal:  Eur Radiol       Date:  2014-11-04       Impact factor: 5.315

2.  Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules.

Authors:  Richard N J Graham; David R Baldwin; Matthew E J Callister; Fergus V Gleeson
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

3.  Computed tomography screening for lung cancer.

Authors:  Pamela M McMahon; David C Christiani
Journal:  BMJ       Date:  2007-02-10

Review 4.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 5.  European and North American lung cancer screening experience and implications for pulmonary nodule management.

Authors:  Arjun Nair; David M Hansell
Journal:  Eur Radiol       Date:  2011-08-10       Impact factor: 5.315

Review 6.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 7.  Lung cancer screening and its efficacy.

Authors:  Motoyasu Sagawa; Katsuo Usuda; Hirokazu Aikawa; Yuichiro Machida; Makoto Tanaka; Masakatsu Ueno; Tsutomu Sakuma
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-10-16

8.  Lung nodule volumetry: segmentation algorithms within the same software package cannot be used interchangeably.

Authors:  H Ashraf; B de Hoop; S B Shaker; A Dirksen; K S Bach; H Hansen; M Prokop; J H Pedersen
Journal:  Eur Radiol       Date:  2010-03-20       Impact factor: 5.315

9.  Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON).

Authors:  K A M van den Bergh; M L Essink-Bot; G J J M Borsboom; E Th Scholten; M Prokop; H J de Koning; R J van Klaveren
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

10.  Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability.

Authors:  Ying Wang; Geertruida H de Bock; Rob J van Klaveren; Peter van Ooyen; Wim Tukker; Yingru Zhao; Monique D Dorrius; Rozemarijn Vliegenthart Proença; Wendy J Post; Matthijs Oudkerk
Journal:  Eur Radiol       Date:  2009-11-18       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.